4-bromo-2-(4-methoxybutyl)-6-methylpyridine-N-oxide | 865156-62-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-bromo-2-(4-methoxybutyl)-6-methylpyridine-N-oxide
• 英文别名: 4-Bromo-2-(4-methoxybutyl)-6-methyl-1-oxidopyridin-1-ium
• CAS: 865156-62-3
• 化学式: C₁₁H₁₆BrNO₂
• 分子量: 274.158
• InChiKey: VQHRJSDEZCFQES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  34.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005090304A1

  公开（公告）日：2005-09-29

  The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  这项发明涉及一般式(I)的新型氨基醇，其中X、R1、R2、R3、R4、R5和R6的定义详细描述在说明书中，以及它们的制备方法和将这些化合物用作药物，特别是作为肾素抑制剂。
• Organic Compounds
  申请人：Herold Peter

  公开号：US20080058320A1

  公开（公告）日：2008-03-06

  The invention relates to novel amino alcohols of the general formula (I) where X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  本发明涉及一种新型的氨基醇，其通式为(I)，其中X，R1，R2，R3，R4，R5和R6分别如详细描述中所定义，以及其制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂。
• 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension
  申请人：Herold Peter

  公开号：US20080280895A1

  公开（公告）日：2008-11-13

  The application relates to novel alkanamides of the general formula (I) where X is —CH 2 — or >CH—OH; (A) R 1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R 2 is C 1 -C 6 -alkyl or C 3 -C 6 -cydoalkyl; R 3 are each independently H, C 1 -C 6 -alkyl, C 1-6 -alkoxycarbonyl or C 1 -C 6 -alkanoyl; R 4 is C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 6 -alkenyl or unsubstituted or substituted arylC 1 -C 6 -alkyl; R 5 is C 1 -C 6 -alkyl, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl, C 1 -C 6 -alkanoyloxy C 1 -C 6 -alkyl, C 1 -C 6 -aminoalkyl, C 1 -C 6 -alkylamino-C 1 -C 6 -alkyl, C 1 -C 6 -dialkylamino-C 1 -C 6 -alkyl, C 1 -C 6 -alkanoylamido-C 1 -C 6 -alkyl, HO(O)C—C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-O—(O)C—C 1 -C 6 -alkyl, H 2 N—C(O)—C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-HN—C(O)—C 1 -C 6 -alkyl, (C 1 , —C 6 -alkyl) 2 N—C(O)—C 1 -C 6 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -alkynyl, cyano-C 1 -C 6 -alkyl, halo-C 1 -C 6 -alkyl, optionally substituted aryl-C o -C 6 -alkyl, optionally substituted C 3 -C 8 -cycloalkyl-C o -C 6 -alkyl or optionally substituted heterocydyl-C o -C 6 -alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.

  该申请涉及到通式（I）的新型烷基酰胺，其中X为—CH2—或>CH—OH；（A）R1为例如可选择取代的杂环基基团或可选择取代的多环不饱和碳氢基团，其中X为羟甲基；R2为C1-C6-烷基或C3-C6-环烷基；R3各自独立地为H、C1-C6-烷基、C1-6-烷氧羰基或C1-C6-酰基；R4为C1-C6-烷基、C3-C6-环烷基、C2-C6-烯基或未取代或取代的芳基C1-C6-烷基；R5为C1-C6-烷基、C1-C6-羟基烷基、C1-C6-烷氧基-C1-C6-烷基、C1-C6-酰氧-C1-C6-烷基、C1-C6-氨基烷基、C1-C6-烷基氨基-C1-C6-烷基、C1-C6-二烷基氨基-C1-C6-烷基、C1-C6-酰胺基-C1-C6-烷基、HO(O)C—C1-C6-烷基、C1-C6-烷基-O—(O)C—C1-C6-烷基、H2N—C(O)—C1-C6-烷基、C1-C6-烷基-HN—C(O)—C1-C6-烷基、（C1，—C6-烷基）2N—C(O)—C1-C6-烷基、C2-C8-烯基、C2-C8-炔基、氰基-C1-C6-烷基、卤代-C1-C6-烷基、可选择取代的芳基-Co-C6-烷基、可选择取代的C3-C8-环烷基-Co-C6-烷基或可选择取代的杂环基-Co-C6-烷基；以及它们的制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂治疗高血压。
• 5-AMINO-4-HYDROXY-7-(PYRIDINYLMETHYL)-ALKANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION
  申请人：Speedel Experimenta AG

  公开号：EP1712548A2

  公开（公告）日：2006-10-18

  The application relates to novel alkanamides of the general formula where X is -CH2- (A) R1 is substituted pyridinyl R2 is C1-C6-alkyl or C3-C6-cycloalkyl; R3 are each independently H, C1-C6-alkyl, C1-6-alkoxycarbonyl or C1-C6-alkanoyl; R4 is C1C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl or unsubstituted or substituted aryl-C1-C6-alkyl; R5 is C1-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkanoyloxy-C1-C6-alkyl, C1-C6-aminoalkyl, C1-C6-alkylamino-C1-C6-alkyl, C1-C6-dialkylamino-C1-C6alkyl, C1-C6-alkanoylamido-C1-C6-alkyl, HO(O)C-C1-C6-alkyl, C1-C6-alkyl-O-(O)C-C1-C6-alkyl, H2N-C(O)-C1-C6-alkyl, C1-C6-alkyl-HN-C(O)-C1-C6-alkyl, (C1-C6-alkyl)2N-C(O)-C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, cyano-C1-C6-alkyl, halo-C1-C6-alkyl, optionally substituted aryl-C0-C6-alkyl, optionally substituted C3-C8-cycloalkyl-C0-C8-alkyl or optionally substituted heterocyclyl-C0-C6-alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.

  本申请涉及通式如下的新型烷酰胺 其中 X 是-CH2- (A) R1 是取代的吡啶基 R2 是 C1-C6 烷基或 C3-C6 环烷基； R3 各自独立地为 H、C1-C6-烷基、C1-6-烷氧基羰基或 C1-C6- 烷酰基； R4 是 C1-C6- 烷基、C3-C6-环烷基、C2-C6-烯基或未取代或取代的芳基-C1-C6-烷基； R5 是 C1-C6- 烷基、C1-C6-羟基烷基、C1-C6-烷氧基-C1-C6-烷基、C1-C6-烷酰氧基-C1-C6-烷基、C1-C6-氨基烷基、C1-C6-烷基氨基-C1-C6-烷基、C1-C6-二烷基氨基-C1-C6-烷基、C1-C6-烷酰氨基-C1-C6-烷基、HO(O)C-C1-C6-烷基、C1-C6-烷基-O-(O)C-C1-C6-烷基、H2N-C(O)-C1-C6-烷基、C1-C6-烷基-HN-C(O)-C1-C6-烷基、(C1-C6-烷基)2N-C(O)-C1-C6-烷基、C2-C8-烯基、C2-C8-炔基、氰基-C1-C6-烷基、卤代-C1-C6-烷基、任选取代的芳基-C0-C6-烷基、任选取代的 C3-C8-环烷基-C0-C8-烷基或任选取代的杂环基-C0-C6-烷基；这些化合物的制备方法和药物用途，特别是作为治疗高血压的肾素抑制剂。
• ORGANIC COMPOUNDS
  申请人：Speedel Experimenta AG

  公开号：EP1725530A1

  公开（公告）日：2006-11-29